Abstracts tagged "treatment and ultrasound"

Abstract Number: 2967 • 2017 ACR/ARHP Annual Meeting
Adding Ultrasound to the Treat-to-Target Strategy Shows No Benefit in Achievement of Remission: Results from the Biodam Cohort
Alexandre Sepriano¹, Sofia Ramiro², Robert B.M. Landewé³, Désirée van der Heijde¹, Sarah Ohrndorf⁴, Oliver FitzGerald⁵, Marina Backhaus⁶, Maggie Larche⁷, Joanne Homik⁸, Alain Saraux⁹, Hilde B. Hammer¹⁰, Lene Terslev¹¹, Mikkel Østergaard¹¹, Gerd R. Burmester¹², Bernard Combe¹³, Maxime Dougados¹⁴, Carol A Hitchon¹⁵, Gilles Boire¹⁶, Robert G. Lambert⁸, Rana Dadashova¹⁷, Joel Paschke¹⁸, Edna Hutchings¹⁷ and Walter P. Maksymowych¹⁷, ¹Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ³University of Amsterdam and Atrium Medical Center, Amsterdam, Netherlands, ⁴Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, ⁵ASRI, Dublin, Ireland, Dublin, Ireland, ⁶Rheumatology/Immunology, Charite University Hospital, Berlin, Germany, ⁷Medicine, McMaster University, Hamilton, ON, Canada, ⁸University of Alberta, Edmonton, AB, Canada, ⁹Rheumatology Department, Rheumatology Department, CHU de la Cavale Blanche, Brest, France, Brest Cedex, France, ¹⁰Dept. of Rheumtology, Diakonhjemmet Hospital, Oslo, Norway, ¹¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark, ¹²Department of Rheumatology and Clinical Immunolgy, Charité University Hospital, Berlin, Germany, ¹³Rheumatology, Lapeyronie Hospital, Montpellier I university, Montpellier, France, ¹⁴Paris-Descartes University,, Paris, France, ¹⁵University of Manitoba, Winnipeg, MB, Canada, ¹⁶Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ¹⁷CaRE Arthritis, Edmonton, AB, Canada, ¹⁸CARE Arthritis, Edmonton, AB, Canada
Background/Purpose: While, a Treat-to-Target strategy (T2T), treating patients with rheumatoid arthritis (RA) towards a certain target (eg. clinical remission; T2T-REM), is highly recommended, several patients…
Abstract Number: 411 • 2017 ACR/ARHP Annual Meeting
Factors That Drive Treatment Recommendation during Rheumatoid Arthritis Patient´s Follow-up, Differ According to Physician Experience
César Sifuentes-Cantú¹, Irazu Contreras-Yañez², Lina Saldarriaga Rivera³, Ana Cecilia Lozada⁴, Marwin Gutierrez⁵ and Virginia Pascual-Ramos¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, ³Instituto Nacional de Rehabilitación, Mexico, Mexico, ⁴Division of musculoskeletal and rheumatic diseases, Instituto Nacional de Rehabilitación, Mexico City, Mexico, ⁵Rheumatology, Instituto Nacional de Rehabilitación, Mexico City, Mexico
Background/Purpose: The management plan for rheumatoid arthritis (RA) might be a relatively simple task if only disease activity is considered but might become more complex…
Abstract Number: 1392 • 2017 ACR/ARHP Annual Meeting
Effect Size Comparison of Ultrasound Measures in Rheumatoid Arthritis
Veena K. Ranganath¹, David Elashoff², Jenny Brook³, Ami Ben-Artzi⁴, Geraldine Navarro⁵, Lynnette Avedikian-Tatosyan⁶, George Karpouzas⁷, William Martin⁵, Tanaz A. Kermani⁵, Soo Choi⁵ and Gurjit S. Kaeley⁸, ¹Medicine/Rheumatology, University of California, Los Angeles, Los Angeles, CA, ²David Geffen School of Medicine,, University of California, Los Angeles, Los Angeles, CA, ³Medicine, David Geffen School of Medicine, UCLA, Los Angeles, CA, ⁴Medicine, Cedars, Beverly Hills, CA, ⁵Medicine, Division of Rheumatology, David Geffen School of Medicine, UCLA, Los Angeles, CA, ⁶Healthcare Partners, Los Angeles, CA, ⁷Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ⁸Rheumatology, University of Florida College of Medicine, Jacksonville, Jacksonville, FL
Background/Purpose: Currently there are several outcome metrics used for the assessment and quantification of musculoskeletal (MSK) ultrasound inflammatory burden in rheumatoid arthritis (RA). This study…
Abstract Number: 2013 • 2017 ACR/ARHP Annual Meeting
Physician Experience and Patient´s Disease Activity Affect the Impact of Musculoskeletal Ultrasound on the Treatment Decision in Rheumatoid Arthritis Patients
César Sifuentes-Cantú¹, Irazu Contreras-Yañez², Marwin Gutierrez³ and Virginia Pascual-Ramos⁴, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, ³Rheumatology, Instituto Nacional de Rehabilitación, Mexico City, Mexico, ⁴Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: In a real clinical setting of RA outpatients, we previously showed that musculoskeletal ultrasound (MUS) added to clinical evaluation impacted the treatment decision in…
Abstract Number: 100 • 2017 Pediatric Rheumatology Symposium
Improvement of Salivary Gland Ultrasound Findings in Juvenile Sjögren’s Syndrome after Systemic Corticosteroid Treatment
Akaluck Thatayatikom¹, Renee F Modica², Daniel S. Hammenfors³, Natalie Jane Shiff¹ and Melissa E Elder², ¹Pediatrics, University of Florida, Gainesville, FL, ²Department of Pediatrics, University of Florida, Gainesville, FL, ³Department of Rheumatology, Haukeland University Hospital, Bergen, Norway
Background/Purpose: Juvenile Sjögren’sSyndrome (jSS) is a rare systemic autoimmune disease affecting predominantly salivary glands (SG) in children who do not meet criteria for SLE or MCTD. Currently, no specific criteria for…
Abstract Number: 1977 • 2016 ACR/ARHP Annual Meeting
Impact of Ultrasound in Treatment Decision of Rheumatoid Arthritis Assessed in Routine Clinical Practice
César Sifuentes-Cantú¹, Lina Saldarriaga-Rivera², Ana Cecilia Lozada², Irazu Contreras-Yañez³, Marwin Gutierrez⁴ and Virginia Pascual-Ramos⁵, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Division of musculoskeletal and rheumatic diseases, Instituto Nacional de Rehabilitación, Mexico City, Mexico, ³Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, ⁴Instituto Nacional de Rehabilitación, Mexico, Mexico, ⁵Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Remission or low disease activity is the therapeutic target for rheumatoid arthritis (RA). There is a consistent body of evidence supporting the value of…
Abstract Number: 1446 • 2014 ACR/ARHP Annual Meeting
Utility of Ultrasound in the Nuffield Orthopaedic Centre Emergency Rheumatology Clinic: Survey of Clinical Effectiveness
Kuljeet Bhamra¹, Catherine Swales¹, Matthew Seymour¹, Catherine McClinton¹ and Peter C. Taylor², ¹Nuffield Department of orthopaedics,rheumatology and musculosketal sciences, University of Oxford, Oxford, United Kingdom, ²NDORMS, Botnar Research Centre, University of Oxford, Oxford, United Kingdom
Background/Purpose The aim of the survey was to evaluate the impact of clinic-based musculoskeletal ultrasonography (MSUS) on diagnosis and management of cases seen in the…
Abstract Number: 798 • 2013 ACR/ARHP Annual Meeting
Targeting Ultrasound Remission In Early Rheumatoid Arthritis – Results Of The Taser Study
James Dale¹, Anne Stirling², Iain B. McInnes¹ and Duncan Porter³, ¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Gartnavel General Hospital, Glasgow, United Kingdom, ³Rheumatology, Gartnavel General Hospital, Glasgow, United Kingdom
Background/Purpose: The TaSER study (NCT00920478) is an open label randomized clinical trial with blinded assessments of outcome. It was designed to test whether the efficacy…
Abstract Number: 808 • 2012 ACR/ARHP Annual Meeting
Power Doppler Is Predictive of Treatment Failure in Early Rheumatoid Arthritis Patients: A One Year Follow-up Study
Karine R. Luz¹, Rita N.V. Furtado¹, Marcelo M. Pinheiro², Giovanna S. Petterle¹ and Jamil Natour¹, ¹Rheumatology Division, Universidade Federal de São Paulo, São Paulo, Brazil, ²Brazilian Registry of Spondyloarthritis, São Paulo, Brazil
Background/Purpose: It is known that ultrasound (US) is a useful test to monitor rheumatoid arthritis (RA) patients. However, to date, no study has shown the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].